Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Minimal Residual Disease Market Size Changed, over the years?
The market size for minimal residual disease has experienced quick expansion in the past few years. It is projected to increase from $1.78 billion in 2024 to $2.01 billion in 2025, with a compound annual growth rate (CAGR) of 12.9%. Factors contributing to its growth during the historic period include a rise in cancer cases, increased spending on research and development, improved affordability of healthcare, an increased occurrence of blood cancer, and heightened public awareness.
How Much Will the Minimal Residual Disease Market Be Worth in 2029?
Expectations suggest that the minimal residual disease market will undergo substantial growth in the coming years, potentially reaching a value of $3.22 billion by 2029, with a compound annual growth rate (CAGR) of 12.5%. This predicted growth during the forecast period is linked to several factors: an increase in cancer patients, a surge in government-driven awareness programs, improved healthcare affordability, heightened disposable income in burgeoning economies, and initiatives by governmental bodies to enhance cancer awareness. Major forecast period trends encompass developments in next-generation sequencing (NGS) technology, standardization of MRD testing, the adoption of personalized MRD monitoring, progress in liquid biopsy technologies, and therapies targeted at minimal residual disease.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp
Which is the Largest Company in the Minimal Residual Disease Market?
Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.
What Are the Main Market Drivers in the Minimal Residual Disease Industry?
The minimal residual disease market’s growth is anticipated to be driven by the rising incidence of cancer. Cancer, a group of diseases defined by the uncontrolled proliferation and spread of aberrant cells within the body, is becoming more common due to reasons such as an aging demographic, increased contact with environmental carcinogens, unhealthy lifestyles, and hereditary susceptibilities. The growing frequency of cancer heightens the requirement for accurate MRD testing to identify any remaining cancer cells, allowing for early detection and tailored treatments. This enhances the prediction of recurrence and improves patient results. For instance, the National Cancer Institute (NCI), a government agency based in the US, reported in May 2024 that nearly 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide in 2022, with forecasts for 2040 predicting 29.9 million new instances and 15.3 million cancer-related fatalities. Consequently, the escalating incidence of cancer is fueling the expansion of the minimal residual disease market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21224&type=smp
How Is the Minimal Residual Disease Market Segments Structured?
The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions
Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
What Strategic Trends Are Transforming the Minimal Residual Disease Market?
Pioneering businesses in the minimal residual disease (MRD) market are prioritizing the development of innovative in vitro diagnostic (IVD) examination services as they strive for personalized treatment options that enhance patient results. IVD testing is a laboratory-based diagnostic approach that identify the remaining cancer cells post-treatment, allowing predictions regarding recurrence and refining therapy. For example, Adaptive Biotechnologies Corporation, an American biotech firm, introduced clonoSEQ Assay, a MRD detection solution for patients with diffuse large B-cell lymphoma (DLBCL) in December 2022. The test utilizes circulating tumor DNA (ctDNA) in blood specimens to provide a supremely sensitive, non-intrusive method of tracking cancer development and identifying early relapse indicators. This assay equips doctors with a more accurate comprehension of a patient’s disease load, aiding in the customization of treatment strategies. The debut of this clonoSEQ Assay, the first MRD test for DLBCL covered by Medicare, ensures its wide availability across all treatment schedules and periods.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report
Which Global Regions Offer the Highest Growth in the Minimal Residual Disease Market?
North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21224
This Report Delivers Insight On:
1. How big is the minimal residual disease market, and how is it changing globally?
2. Who are the major companies in the minimal residual disease market, and how are they performing?
3. What are the key opportunities and risks in the minimal residual disease market right now?
4. Which products or customer segments are growing the most in the minimal residual disease market?
5. What factors are helping or slowing down the growth of the minimal residual disease market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model